Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 16 May, 2018 the following resolutions were made:
The AGM adopted the income statements and balance sheets for 2017 and decided that no dividend for the financial year 2017 will be paid. Retained earnings and the company's loss for the year will be carried forward.
The Board of Directors and CEO were discharged from liability for the financial year 2017.
An annual remuneration of SEK 500 000 will be paid to the chairman of the Board and SEK 200 000 to each of the other external directors. Further, it was decided that an annual remuneration of SEK 100 000 will be paid to each chairman of the Audit Committee and Remuneration Committee. No separate remuneration will be paid to the other committee members.
The AGM decided that the Board shall consist of five members, with no alternate directors. Board members Mia Arnhult, Christian Kinch, Marie Wickman-Chanteraeu and Svante Östblom were re-elected. Jan Ståhlberg was elected new Board member and Chairman of the Board.
The AGM decided to re-elect Deloitte AB as auditors and that remuneration to the auditors shall be paid according to approved invoices.
The proposed changes to the instructions for the Nomination Committee, to increase the number of owner appointed members from three to four were adopted.
The AGM adopted the proposed, unchanged guidelines for compensation to senior management.
For further information, please contact:
Cecilia Edström, CFO, cell phone: +46 72 226 23 28
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com